Medscape October 14, 2025
In the last half-decade, the perception of psychedelics has radically shifted in both the public eye and medicine. Once viewed as illicit, many doctors, patients, and state and local governments are reframing the Schedule I substances as a potential source of relief.
As many as 50% of generalized anxiety cases and 30% of depression cases don’t respond to first-line treatments. Emerging evidence suggests psychedelics could be an antidote for these patients. Combined with psychotherapy, psilocybin and ketamine have shown some success against treatment-resistant depression. Midomafetamine (MDMA)-assisted therapy has shown some success in treating posttraumatic stress disorder (PTSD).
Neither psilocybin nor MDMA-assisted therapy is FDA-approved, but both are being reviewed in clinical trials overseen by the FDA. Facilities that dispense psilocybin...
Today's Sponsors
Today's Sponsor